Journal
DIABETIC MEDICINE
Volume 31, Issue 1, Pages E1-E5Publisher
WILEY-BLACKWELL
DOI: 10.1111/dme.12259
Keywords
-
Categories
Ask authors/readers for more resources
BackgroundHepatocyte nuclear factor4 alpha (HNF4A) gene mutations have a well-recognized role in maturity-onset diabetes of the young and have recently been described in congenital hyperinsulinism. A biphasic phenotype has been postulated, with macrosomia and congenital hyperinsulinism in infancy, and diabetes in young adulthood. In this case series, we report three children with HNF4A mutations (two de novo) and diazoxide-responsive congenital hyperinsulinism, highlighting the potential for ongoing diazoxide requirement and the importance of screening for these mutations even in the absence of family history. Case reportsAll patients presented with macrosomia (mean birthweight 4.26kg) and hyperinsulinaemic hypoglycaemia soon after birth (median age 1day). All three (age range 7months to 11years 10months) remain on diazoxide therapy, with dose requirements increasing in one patient. There was no prior family history of diabetes, neonatal hypoglycaemia or macrosomia. Parents were screened for HNF4A mutations post-diagnosis and one father was subsequently found to have maturity-onset diabetes of the young. ConclusionsThis case series follows the evolving course of three patients with confirmed HNF4A-mediated congenital hyperinsulinism, highlighting (1) the variable natural history of these mutations, (2) the potential for prolonged diazoxide requirement, even into adolescence, and (3) the need for screening, regardless of family history.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available